Literature DB >> 20362762

Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report.

Matthias Göllner1, Stefan Holst, Matthias Fenner, Johannes Schmitt.   

Abstract

Bisphosphonate-induced osteonecrosis of the jaws (BONJ) is reported frequently in patients receiving oral or intravenous bisphosphonates. To minimize potential complications, dental treatment must be performed with care. There are invasive and noninvasive treatment options for patients with active BONJ or a history of this complication. This clinical report describes the prosthodontic treatment of a patient who developed BONJ after receiving intravenous bisphosphonates (pamidronate). Because of the recurrent incidence of BONJ, noninvasive prosthetic therapy with telescopic overdentures and a heat-polymerized resilient liner was provided. After 2 years, there were no biological or technical complications. Copyright 2010 The Editorial Council of the Journal of Prosthetic Dentistry. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362762     DOI: 10.1016/S0022-3913(10)00052-1

Source DB:  PubMed          Journal:  J Prosthet Dent        ISSN: 0022-3913            Impact factor:   3.426


  3 in total

Review 1.  Medication-related osteonecrosis of the jaw: Prosthodontic considerations.

Authors:  Islam E Ali; Yuka Sumita
Journal:  Jpn Dent Sci Rev       Date:  2021-12-18

2.  Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature.

Authors:  F Longo; A Guida; C Aversa; E Pavone; G Di Costanzo; L Ramaglia; F Ionna
Journal:  Int J Dent       Date:  2014-06-10

Review 3.  The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.

Authors:  Olga Di Fede; Vera Panzarella; Rodolfo Mauceri; Vittorio Fusco; Alberto Bedogni; Lorenzo Lo Muzio; Giuseppina Campisi
Journal:  Biomed Res Int       Date:  2018-09-16       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.